Q2 2022 EPS Estimates for GSK plc (NYSE:GSK) Reduced by Analyst

GSK plc (NYSE:GSKGet Rating) – Stock analysts at Jefferies Financial Group decreased their Q2 2022 EPS estimates for shares of GSK in a note issued to investors on Thursday, June 16th. Jefferies Financial Group analyst P. Welford now expects that the pharmaceutical company will earn $0.67 per share for the quarter, down from their prior forecast of $0.69. The consensus estimate for GSK’s current full-year earnings is $3.18 per share. Jefferies Financial Group also issued estimates for GSK’s Q3 2022 earnings at $1.14 EPS, FY2024 earnings at $4.14 EPS, FY2025 earnings at $4.91 EPS and FY2026 earnings at $5.62 EPS.

GSK (NYSE:GSKGet Rating) last posted its quarterly earnings data on Wednesday, April 27th. The pharmaceutical company reported $0.88 EPS for the quarter, topping analysts’ consensus estimates of $0.77 by $0.11. GSK had a net margin of 14.03% and a return on equity of 28.13%. The company had revenue of $13.12 billion during the quarter, compared to the consensus estimate of $11.97 billion.

Several other equities research analysts also recently issued reports on the stock. Barclays raised their target price on shares of GSK from GBX 1,775 ($21.54) to GBX 1,800 ($21.85) in a research note on Friday, April 29th. Stifel Nicolaus assumed coverage on shares of GSK in a research note on Monday, February 28th. They issued a “hold” rating for the company. StockNews.com upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 11th. Finally, JPMorgan Chase & Co. raised their target price on shares of GSK from GBX 1,740 ($21.12) to GBX 1,900 ($23.06) in a research note on Thursday, April 28th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, one has given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $1,850.00.

Shares of NYSE:GSK opened at $41.64 on Friday. GSK has a 52-week low of $37.80 and a 52-week high of $46.97. The company has a market capitalization of $105.84 billion, a P/E ratio of 15.03, a price-to-earnings-growth ratio of 1.87 and a beta of 0.64. The company has a 50-day simple moving average of $44.37 and a 200 day simple moving average of $43.76. The company has a debt-to-equity ratio of 1.29, a quick ratio of 0.95 and a current ratio of 1.19.

Institutional investors have recently added to or reduced their stakes in the business. Wedbush Securities Inc. increased its holdings in shares of GSK by 1.5% during the fourth quarter. Wedbush Securities Inc. now owns 15,370 shares of the pharmaceutical company’s stock worth $678,000 after purchasing an additional 222 shares during the period. KG&L Capital Management LLC increased its holdings in shares of GSK by 0.8% during the first quarter. KG&L Capital Management LLC now owns 29,611 shares of the pharmaceutical company’s stock worth $1,290,000 after purchasing an additional 225 shares during the period. Koss Olinger Consulting LLC increased its holdings in shares of GSK by 3.4% during the first quarter. Koss Olinger Consulting LLC now owns 7,299 shares of the pharmaceutical company’s stock worth $318,000 after purchasing an additional 242 shares during the period. Hohimer Wealth Management LLC increased its holdings in shares of GSK by 0.4% during the fourth quarter. Hohimer Wealth Management LLC now owns 65,177 shares of the pharmaceutical company’s stock worth $2,874,000 after purchasing an additional 246 shares during the period. Finally, Steel Peak Wealth Management LLC increased its holdings in shares of GSK by 4.6% during the first quarter. Steel Peak Wealth Management LLC now owns 5,543 shares of the pharmaceutical company’s stock worth $241,000 after purchasing an additional 246 shares during the period. 32.76% of the stock is currently owned by hedge funds and other institutional investors.

The business also recently declared a quarterly dividend, which will be paid on Friday, July 1st. Shareholders of record on Friday, May 20th will be issued a $0.3496 dividend. The ex-dividend date of this dividend is Thursday, May 19th. This represents a $1.40 annualized dividend and a yield of 3.36%. GSK’s dividend payout ratio is currently 49.46%.

About GSK (Get Rating)

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

Further Reading

Earnings History and Estimates for GSK (NYSE:GSK)

Want More Great Investing Ideas?

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.